Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Biotech & Beers – Newcastle

Join Bionow for an informal networking evening on 10th June, the night before BioFocus 2025. Open to all, this relaxed, agenda-free event is a fantastic [...]

Go to Top